Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma
Pemigatinib – a oral FGFR1-3 inhibitor has shown efficacy and safety in patients with advanced/metastatic cholangiocarcinoma publish in the Lancet Oncol 2020. In this MEDtalk Abou-Alfa K. Ghassan present the update FIGHT-202 study, where overall survival for responders was more than twice as long vs for non-responders
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.